A Pilot Study of Abiraterone Acetate in African American/Black Patients with Castration Resistant Prostate Cancer

ID Number 12-1727

Principal Investigator(s)
Matthew Galsky

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to evaluate the effects of abiraterone acetate on prostate cancer in African American/Black men and will determine if difference in genes measured in the blood impact the likelihood of prostate cancer to respond to treatment with abiraterone acetate.   African American/Black men have the highest rate of prostate cancer among men in the United States and their risk of death from the disease is higher than that of Caucasian men. There are likely several reasons for this. One reason may be that there may be differences in particular genes in the body, or in the prostate cancer that make prostate cancer more aggressive in African American/Black men. These genes may also impact the effects of abiraterone acetate on prostate cancer.

Abiraterone acetate is a drug that is approved by the United States Food and Drug Administration (FDA) as a prescription medication to treat men with metastatic prostate cancer that has progressed despite receiving chemotherapy. While studies of abiraterone acetate have included some African American/Black patients, there have been no studies of abiraterone acetate performed exclusively in African American/Black patients to further define the effects, both good and bad.

You are being given information about becoming a volunteer in a research study.  You may qualify to participate in this research study because you have been diagnosed with prostate cancer that has spread to other parts of your body (meaning the cancer has “metastasized”).  

In this study you will receive abiraterone acetate, a pill used to treat prostate cancer that reduces the production of male hormones made by the adrenal gland, in combination with prednisone, a steroid pill used to treat prostate cancer.

Contact Information
Annie Lincoln
(212) 824-7822

Recruiting Patients: No